Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463710 · ClinicalTrials.gov registry record
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
A clinical trial, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 150
- Enrollment target
NCT00463710 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 150 participants.
The verdict
NCT00463710 has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
Phase IV open label, single-blind study, post-marketing, 1-year MRI observational study evaluating effect of Avonex® monotherapy (6.0 MIU administered i.m. each week) on the year-to-year changes in two annual measures-magnetization transfer imaging and diffusion-weighted imaging in patients with either relapsing-remitting (RR) or secondary-progressive (SP) multiple sclerosis (MS). One hundred fifty (150) patients with RR and SP MS-followed at the Jacobs Neurological Institute, University at Buffalo, Buffalo NY-who satisfy both inclusion and exclusion criteria will be included. They will be assessed at baseline and at 12 months with MRI and clinical examinations.
Interventions
- DRUG Avonex® monotherapy (6.0 MIU administered i.m. each week)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00463710
The ClinicalTrials.gov registry entry for NCT00463710 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avonex® monotherapy (6.0 MIU administered i.m. each week) is the first listed.
NCT00463710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00463710 about?
NCT00463710 is a clinical study titled "Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS". Phase IV open label, single-blind study, post-marketing, 1-year MRI observational study evaluating effect of Avonex® monotherapy (6.0 MIU administered i.m. each week) on the year-to-year changes in two annual measures-magnetization transfer imaging and diffusion-weighted imaging in patients with eit...
What is the current status of trial NCT00463710?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2005-06. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00463710?
The interventions under investigation include: Avonex® monotherapy (6.0 MIU administered i.m. each week) (DRUG).
Who is sponsoring clinical trial NCT00463710?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.